Reporter

Shana Alford named director of Evaluation and Equity

Public health researcher Shana Alford has joined VUMC as director of Evaluation and Equity.
This position, which spans the Office of Health Equity and the Office of Diversity and Inclusion, was created as part of VUMC’s Racial Equity Plan.

Julie Lounds Taylor and Pablo Juárez appointed new co-directors of the Vanderbilt Kennedy Center University Center for Excellence in Developmental Disabilities

The Vanderbilt Kennedy Center (VKC) has announced new leadership for its University Center for Excellence in Developmental Disabilities (UCEDD). Julie Lounds Taylor, PhD, and Pablo Juárez, MEd, BCBA, LBA, have succeeded Elise McMillan, JD, who retired June 30.

Vanderbilt investigators land Keck Foundation grant for groundbreaking genetic research

Vanderbilt scientists have received a $1.2 million award from the W. M. Keck Foundation for their groundbreaking project, “Genetic Intolerance Patterns as a Treasure Map to Genes that Define Us as Human.”

William Nolan and his fianceé, Cassie Rooke, enjoy active lives, including taking long walks with their dog, Grizz. Nolan volunteers as a Trauma Peer Visitor to support others hospitalized with serious trauma.

Former patient steps up to help others with traumatic injuries

Former patient William Nolan is now a VUMC Trauma Peer Visitor, supporting others recovering from life-changing injuries.

Selenium signal found in colorectal cancer: study

An antioxidant transporter of the trace mineral selenium that protects against inflammatory bowel disease has the opposite effect in colorectal cancer, where it promotes tumor growth, researchers at Vanderbilt University Medical Center have reported.

Research by Ann Richmond, PhD, second from left, Chi Yan, PhD, left, Kensey Bergdorf, PhD, JinMing Yang, PhD, and colleagues is leading to new insights on melanoma tumor formation and growth.

Study identifies key regulator of melanoma development

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

1 34 35 36 37 38 770